icon-folder.gif   Conference Reports for NATAP  
 
  53rd ICAAC Interscience Conference on
Antimicrobial Agents and Chemotherapy
September 10-13, 2013, Denver CO
Back grey_arrow_rt.gif
 
 
 
Long-Term Tolerability of Elvitegravir/cobicistat/emtricitabine/tenofovir DF Compared to Efavirenz/emtricitabine/tenofovir DF or Ritonavir-Boosted Atazanavir Plus Emtricitabine/tenofovir DF in Treatment-Naive HIV-1-Infected Subjects
 
 
  Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 10-13, 2013Denver, CO, USA
 
P Shalit1, J Gallant2, A Mills3, G Crofoot4, T Nguyen5, H Liu5, M Rhee5, J Szwarcberg5
1Peter Shalit, MD, Seattle, WA; 2Southwest CARE Center, Santa Fe, New Mexico; 3Anthony Mills, MD, Inc., Los Angeles, CA; 4Gordon Crofoot, MD, Inc., Houston, TX; 5Gilead Sciences, Inc., Foster City, CA

ICAAC1.gif

ICAAC2.gif

ICAAC3.gif

ICAAC4.gif

ICAAC5.gif

ICAAC6.gif

ICAAC7.gif

ICAAC8.gif